Polymorphic variants in α-methylacyl-CoA racemase and prostate cancer

Prostate

Volumn 67, Issue 14, 2007, Pages 1487-1497

  Daugherty, Sarah E ^a,b,g   Shugart, Yin Yao ^b   Platz, Elizabeth A ^b,c,d   Fallin, M Daniele ^b   Isaacs, William B ^c,d   Pfeiffer, Ruth M ^a   Welch, Robert ^e   Huang, Wen Yi ^a   Reding, Douglas ^f   Hayes, Richard B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e SAIC FREDERICK INC   (United States)

^f MARSHFIELD CLINIC   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

AMACR; Branched chain fatty acids; Haplotypes; Ibuprofen; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DRUG ACTIVATION; FAMILY HISTORY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CHEMOPREVENTION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IBUPROFEN; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; UNITED STATES;

EID: 35148816045     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20635     Document Type: Article

References (44)

1. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-1404.
2. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002;62:2220-2226.
3. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-1670.
4. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: A novel tumor marker overexpressed in several human cancer sand their precursor lesions. Am J Surg Pathol 2002;26:926-931.
5. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003;63:7365-7376.
6. Zheng SL, Chang BL, Faith DA, Johnson JR, Isaacs SD, Hawkins GA, Turner A, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res 2002;62:6485-6488.
7. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1108-1111.
8. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005;14:390-396.
9. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncol Rep 2000;7:169-170.
10. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002;13:427-434.
11. Perron L, Bairati I, Moore L, Meyer F. Dosage duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-415.
12. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-225.
13. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: Systematic review and meta-analysis. Br J Cancer 2004;90:93-99.
14. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-515.
15. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-980.
16. Tan SC, Patel BK, Jackson SH, Swift CG, Hutt AJ. Ibuprofen stereochemistry: Double-the-trouble? Enantiomer 1999;4:195-203.
17. Knihinicki RD, Day RO, Williams KM. Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-II. Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters. Biochem Pharmacol 1991;42:1905-1911.
18. Zomer AW, van Der BB, Jansen GA, Wanders RJ, Poll-The BT, Der Saag PT. Pristanic acid and phytanic acid: Naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res 2000;41:1801-1807.
19. Xu J, Thornburg T, Turner AR, Vitolins M, Case D, Shadle J, Hinson L, Sun J, Liu W, Chang B, Adams TS, Zheng SL, Torti FM. Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 2005;63:209-214.
20. Mobley JA, Leav I, Zielie P, Wotkowitz C, Evans J, Lam YW, L'Esperance BS, Jiang Z, Ho SM. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 2003;12:775-783.
21. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
22. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, Caporaso N, Ziegler RG, Johnson CC, Weissfeld JL, Hoover RN, Hartge P, Palace C, Gohagan JK. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:349S-355S.
23. De Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-1223.
24. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
25. Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, Eckert A, Beerman M, Miller E, Bergen A, Rothman N, Strausberg R, Chanock SJ. SNP500Cancer: A public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-D621.
26. Tippett KS, Cypel YS. Design and operation: The continuing survey of food intakes by individuals and the diet and health knowledge survey, 1994-96. In: Continuing survey of food intakes by individuals 1994-96. Nationwide Food Surveys Rep No. 96-1. 1998. US Department of Agriculture, Agricultural Research Service. Ref Type: Report.
27. Lewontin RC, Feldman MW. A general asymptotic property of two-locus selection models. Theor Popul Biol 1988;34:177-193.
28. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-322.
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434.
31. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
32. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000;67:947-959.
33. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.
34. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-741.
35. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-596.
36. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-8623.
37. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review. J Urol 2003;169:2352-2359.
38. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: Progress and perspective. Cancer Lett 2004;215:1-20.
39. Brown P, Mei G, Gibberd F, Burston D, Mayne P, McClinchy J, Sidey M. Diet and Refsum's disease. The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 1993;6:295-305.
40. Xu J, Thornburg T, Turner AR, Vitolins M, Case D, Shadle J, Hinson L, Sun J, Liu W, Chang B, Adams TS, Zheng SL, Torti FM. Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 2005;63:209-214.
41. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
42. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
43. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-3814.
44. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2004;63:316-323.